Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity

Mark T. Nolan, Juan Carlos Plana, Paaladinesh Thavendiranathan, Leslee Shaw, Lei Si, Thomas H. Marwick

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness model compared strain-guided cardioprotection with other protective strategies using a health care payer perspective and five-year time horizon. 

Methods: Three cardioprotection strategies were assessed: 1) usual care (EF-guided cardioprotection, EFGCP) with cardioprotection initiated on diagnosis of LVEF-defined cardiotoxicity (EF-CTX), 2) universal cardioprotection (UCP) for all such patients, and 3) strain-guided cardioprotection (SGCP - treatment of patients with subclinical cardiotoxicity [S-CTX]). A Markov model, informed by the published literature on transitional probabilities, costs and quality-adjusted life years (QALYs) was developed to assess the incremental cost-effectiveness ratio (ICER). Costs, effects and ICER of each specified cardioprotective strategy were assessed over a 5-year range, with sensitivity analyses for significant variables. 

Results: In the reference case of a 49 year old woman with stage IIb breast cancer treated with sequential anthracyclines and trastuzumab, strain-guided cardioprotection (3.79 QALYS and $4159 cost over 5 years) dominated both UCP (3.64 QALYs and $5967 cost over 5 years) and EFGCP (3.53 QALYs and $7033 cost over five years). Model results were dependent on the probabilities of patients developing subclinical LV dysfunction, with UCP dominating alternative strategies at probabilities ≥ 51%. Variations in the cost of cardioprotective medications and probabilities of cardioprotection side-effects had no effect on model conclusions. 

Conclusions: In patients at risk of chemotherapy-related cardiotoxicity, strain-guided cardioprotection provides more QALYs at lower cost than standard care or uniform cardioprotection.

LanguageEnglish
Pages336-345
Number of pages10
JournalInternational Journal of Cardiology
Volume212
DOIs
Publication statusPublished - 1 Jun 2016
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Quality-Adjusted Life Years
Costs and Cost Analysis
Drug Therapy
Peptide Elongation Factor 2
Peptide Elongation Factor 1
Anthracyclines
Cardiotoxicity
Heart Failure
Breast Neoplasms
Health
Neoplasms

Keywords

  • Cardiotoxicity
  • Chemotherapy
  • Cost effectiveness
  • Decision-making

Cite this

Nolan, Mark T. ; Plana, Juan Carlos ; Thavendiranathan, Paaladinesh ; Shaw, Leslee ; Si, Lei ; Marwick, Thomas H. / Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity. In: International Journal of Cardiology. 2016 ; Vol. 212. pp. 336-345.
@article{b13100a0ac1b461999f6754be662b3d0,
title = "Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity",
abstract = "Background: Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness model compared strain-guided cardioprotection with other protective strategies using a health care payer perspective and five-year time horizon. Methods: Three cardioprotection strategies were assessed: 1) usual care (EF-guided cardioprotection, EFGCP) with cardioprotection initiated on diagnosis of LVEF-defined cardiotoxicity (EF-CTX), 2) universal cardioprotection (UCP) for all such patients, and 3) strain-guided cardioprotection (SGCP - treatment of patients with subclinical cardiotoxicity [S-CTX]). A Markov model, informed by the published literature on transitional probabilities, costs and quality-adjusted life years (QALYs) was developed to assess the incremental cost-effectiveness ratio (ICER). Costs, effects and ICER of each specified cardioprotective strategy were assessed over a 5-year range, with sensitivity analyses for significant variables. Results: In the reference case of a 49 year old woman with stage IIb breast cancer treated with sequential anthracyclines and trastuzumab, strain-guided cardioprotection (3.79 QALYS and $4159 cost over 5 years) dominated both UCP (3.64 QALYs and $5967 cost over 5 years) and EFGCP (3.53 QALYs and $7033 cost over five years). Model results were dependent on the probabilities of patients developing subclinical LV dysfunction, with UCP dominating alternative strategies at probabilities ≥ 51{\%}. Variations in the cost of cardioprotective medications and probabilities of cardioprotection side-effects had no effect on model conclusions. Conclusions: In patients at risk of chemotherapy-related cardiotoxicity, strain-guided cardioprotection provides more QALYs at lower cost than standard care or uniform cardioprotection.",
keywords = "Cardiotoxicity, Chemotherapy, Cost effectiveness, Decision-making",
author = "Nolan, {Mark T.} and Plana, {Juan Carlos} and Paaladinesh Thavendiranathan and Leslee Shaw and Lei Si and Marwick, {Thomas H.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.ijcard.2016.02.137",
language = "English",
volume = "212",
pages = "336--345",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier",

}

Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity. / Nolan, Mark T.; Plana, Juan Carlos; Thavendiranathan, Paaladinesh; Shaw, Leslee; Si, Lei; Marwick, Thomas H.

In: International Journal of Cardiology, Vol. 212, 01.06.2016, p. 336-345.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity

AU - Nolan, Mark T.

AU - Plana, Juan Carlos

AU - Thavendiranathan, Paaladinesh

AU - Shaw, Leslee

AU - Si, Lei

AU - Marwick, Thomas H.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness model compared strain-guided cardioprotection with other protective strategies using a health care payer perspective and five-year time horizon. Methods: Three cardioprotection strategies were assessed: 1) usual care (EF-guided cardioprotection, EFGCP) with cardioprotection initiated on diagnosis of LVEF-defined cardiotoxicity (EF-CTX), 2) universal cardioprotection (UCP) for all such patients, and 3) strain-guided cardioprotection (SGCP - treatment of patients with subclinical cardiotoxicity [S-CTX]). A Markov model, informed by the published literature on transitional probabilities, costs and quality-adjusted life years (QALYs) was developed to assess the incremental cost-effectiveness ratio (ICER). Costs, effects and ICER of each specified cardioprotective strategy were assessed over a 5-year range, with sensitivity analyses for significant variables. Results: In the reference case of a 49 year old woman with stage IIb breast cancer treated with sequential anthracyclines and trastuzumab, strain-guided cardioprotection (3.79 QALYS and $4159 cost over 5 years) dominated both UCP (3.64 QALYs and $5967 cost over 5 years) and EFGCP (3.53 QALYs and $7033 cost over five years). Model results were dependent on the probabilities of patients developing subclinical LV dysfunction, with UCP dominating alternative strategies at probabilities ≥ 51%. Variations in the cost of cardioprotective medications and probabilities of cardioprotection side-effects had no effect on model conclusions. Conclusions: In patients at risk of chemotherapy-related cardiotoxicity, strain-guided cardioprotection provides more QALYs at lower cost than standard care or uniform cardioprotection.

AB - Background: Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness model compared strain-guided cardioprotection with other protective strategies using a health care payer perspective and five-year time horizon. Methods: Three cardioprotection strategies were assessed: 1) usual care (EF-guided cardioprotection, EFGCP) with cardioprotection initiated on diagnosis of LVEF-defined cardiotoxicity (EF-CTX), 2) universal cardioprotection (UCP) for all such patients, and 3) strain-guided cardioprotection (SGCP - treatment of patients with subclinical cardiotoxicity [S-CTX]). A Markov model, informed by the published literature on transitional probabilities, costs and quality-adjusted life years (QALYs) was developed to assess the incremental cost-effectiveness ratio (ICER). Costs, effects and ICER of each specified cardioprotective strategy were assessed over a 5-year range, with sensitivity analyses for significant variables. Results: In the reference case of a 49 year old woman with stage IIb breast cancer treated with sequential anthracyclines and trastuzumab, strain-guided cardioprotection (3.79 QALYS and $4159 cost over 5 years) dominated both UCP (3.64 QALYs and $5967 cost over 5 years) and EFGCP (3.53 QALYs and $7033 cost over five years). Model results were dependent on the probabilities of patients developing subclinical LV dysfunction, with UCP dominating alternative strategies at probabilities ≥ 51%. Variations in the cost of cardioprotective medications and probabilities of cardioprotection side-effects had no effect on model conclusions. Conclusions: In patients at risk of chemotherapy-related cardiotoxicity, strain-guided cardioprotection provides more QALYs at lower cost than standard care or uniform cardioprotection.

KW - Cardiotoxicity

KW - Chemotherapy

KW - Cost effectiveness

KW - Decision-making

UR - http://www.scopus.com/inward/record.url?scp=84962890449&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.02.137

DO - 10.1016/j.ijcard.2016.02.137

M3 - Article

VL - 212

SP - 336

EP - 345

JO - International Journal of Cardiology

T2 - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -